Sanofi Reports Results of SAR442168 in P-IIb Study for Relapsing Multiple Sclerosis

 Sanofi Reports Results of SAR442168 in P-IIb Study for Relapsing Multiple Sclerosis

Sanofi; Reports; Results; SAR442168; P-IIb; Study; Relapsing Multiple Sclerosis

Shots:

  • The P-IIb study involves assessing SAR442168 vs PBO in patients with recurring MS. The one group of patients received 4 doses of SAR442168 @12wks., then crossed over to PBO @4wks. while the other group of patients received PBO @4wks. before crossing over to SAR442168
  • The P-IIb study resulted in meeting its 1EPs i.e. reduction in disease activity associated with MS as measured by MRI, demonstrated reduction of gadolinium (Gd)-enhancing T1-hyperintense brain lesions @12wks. and is well tolerated with no new safety signals
  • SAR442168 (PO) is an investigational, brain penetrant BTK inhibitor with its anticipated initiation of P-III studies in mid-2020. Additionally, Sanofi got global rights to develop and commercialize SAR442168 under a license agreement with Principia Biopharma signed in Nov’2017

Click here ­to­ read full press release/ article | Ref: Sanofi  | Image: Youtube

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post